Equities Analysts Issue Forecasts for USANA Health Sciences, Inc.’s FY2022 Earnings (NYSE:USNA)


USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) – Equities researchers at DA Davidson reduced their FY2022 earnings per share estimates for shares of USANA Health Sciences in a note issued to investors on Wednesday, April 27th. DA Davidson analyst L. Weiser now anticipates that the company will earn $5.22 per share for the year, down from their prior forecast of $5.50. DA Davidson also issued estimates for USANA Health Sciences’ FY2023 earnings at $5.86 EPS.

Several other research firms have also weighed in on USNA. TheStreet lowered shares of USANA Health Sciences from a “b” rating to a “c+” rating in a report on Wednesday, February 9th. Zacks Investment Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 13th. Finally, StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday . Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $105.00.

Shares of USNA stock opened at $75.93 on Thursday. The firm’s 50 day moving average price is $82.15 and its two-hundred day moving average price is $92.95. The stock has a market cap of $1.46 billion, a PE ratio of 13.30 and a beta of 0.87. USANA Health Sciences has a 52-week low of $71.19 and a 52-week high of $107.85.

USANA Health Sciences (NYSE:USNA – Get Rating) last announced its quarterly earnings data on Tuesday, April 26th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. USANA Health Sciences had a net margin of 9.82% and a return on equity of 28.84%. During the same period in the previous year, the firm earned $1.45 EPS.

A number of hedge funds have recently modified their holdings of USNA. Pzena Investment Management LLC increased its stake in USANA Health Sciences by 365.6% in the 4th quarter. Pzena Investment Management LLC now owns 445,632 shares of the company’s stock valued at $45,098,000 after buying an additional 349,924 shares during the last quarter. Norges Bank bought a new position in shares of USANA Health Sciences in the 4th quarter valued at about $12,109,000. Allspring Global Investments Holdings LLC bought a new position in shares of USANA Health Sciences in the 4th quarter valued at about $5,503,000. Goldman Sachs Group Inc. grew its position in shares of USANA Health Sciences by 219.9% ​​in the 4th quarter. Goldman Sachs Group Inc. now owns 71,316 shares of the company’s stock valued at $7,217,000 after acquiring an additional 49,023 shares during the period . Finally, Credit Suisse AG grew its position in shares of USANA Health Sciences by 371.5% in the 4th quarter. Credit Suisse AG no w owns 51,825 shares of the company’s stock valued at $5,245,000 after acquiring an additional 40,833 shares during the period. Hedge funds and other institutional investors own 54.82% of the company’s stock.

In related news, insider Joshua Foukas sold 3,303 shares of the firm’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $89.93, for a total transaction of $297,038.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert A. Fuller sold 312 shares of USANA Health Sciences stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $89.62, for a total transaction of $27,961.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,653 shares of company stock worth $600,825. 0.36% of the stock is currently owned by company insiders.

USANA Health Sciences Company Profile (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups ; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Read More

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)



Receive News & Ratings for USANA Health Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for USANA Health Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published.